《美股业绩》雪佛龙季度纯利跌61% 受下游业务拖累
道指成分股,美国石油巨擘雪佛龙(Chervon)(CVX.US)公布首季业绩。季度纯利13.77亿美元,按年跌61%,去年第四季亏损6.65亿美元。每股季度摊薄纯利72美仙,经调整後为每股90美仙,符合市场预期。季度收入320.29亿美元,按年升1.7%,高於市场预期的303.7亿美元。
雪佛龙季内产量为每日312万桶油当量,按年跌4%。美国上游业务季度溢利9.41亿美元,按年增加7亿美元。每桶美国石油平均销售价格为48美元,按年升11美元。公司决定增加派息4%。公司表示,纯利下跌受下游业务毛利率及美国南部寒潮拖累。
雪佛龙股价上周五(30日)跌3.6%,报103.07美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.